Salim Syed

Stock Analyst at Mizuho

(2.31)
# 2,733
Out of 5,045 analysts
75
Total ratings
43.33%
Success rate
0.39%
Average return

Stocks Rated by Salim Syed

Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16$14
Current: $2.09
Upside: +569.86%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103$84
Current: $61.99
Upside: +35.51%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207$169
Current: $147.86
Upside: +14.30%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235$280
Current: $291.77
Upside: -4.03%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100$117
Current: $118.50
Upside: -1.27%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19$22
Current: $8.26
Upside: +166.34%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113$163
Current: $43.52
Upside: +274.54%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25$18
Current: $14.06
Upside: +28.02%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $22.65
Upside: +50.11%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82$99
Current: $62.56
Upside: +58.25%
Maintains: Buy
Price Target: $60$53
Current: $66.62
Upside: -20.44%
Maintains: Buy
Price Target: $28$21
Current: $1.73
Upside: +1,113.87%
Maintains: Buy
Price Target: $168$36
Current: $30.99
Upside: +16.17%